传统乳头状癌中有多少乳头?235例单发包裹性甲状腺乳头状癌的临床循证病理研究,聚焦NIFTP诊断
该研究对235例既往诊断为单发包裹性甲状腺乳头状癌(U-EPTC)的病例进行精细组织病理学检查,其中100例检测BRAFV600E和NRASQ61R免疫组化。结果显示淋巴结转移仅见于乳头比例≥1%的肿瘤,非侵袭性U-EPTC中N1仅见于乳头≥10%者,且乳头比例越高BRAFV600E频率越高、NRASQ61R越低。结论支持将NIFTP诊断标准恢复为无真性乳头(而非<1%乳头)。
要点
- 淋巴结转移仅见于乳头比例≥1%的U-EPTC,无论侵袭状态。
- 非侵袭性U-EPTC中N1仅见于乳头≥10%的肿瘤。
- 乳头比例越高,BRAFV600E频率越高、NRASQ61R越低。
核心结论
- 在U-EPTC中,高乳头比例、淋巴结转移与BRAF+/RAS-基因型强相关,与侵袭状态无关。
- 乳头<1%的肿瘤未见淋巴结转移,支持将NIFTP诊断标准恢复为无真性乳头。
研究设计与样本
- 对235例既往诊断为单发包裹性甲状腺乳头状癌(U-EPTC)的病例进行精细组织病理学检查。
- 其中100例进行BRAFV600E和NRASQ61R免疫组化检测。
主要发现
- 27例(12%)在初次切除时存在淋巴结转移(N1)。
- N1组中89%的肿瘤含≥50%乳头,而N0/Nx组为13%。
- 淋巴结转移仅见于乳头≥1%的肿瘤;非侵袭性U-EPTC(n=161)中N1仅见于乳头≥10%的肿瘤。
- 乳头比例越高,BRAFV600E频率越高、NRASQ61R越低;26例NRAS阳性病例均无淋巴结转移。
- 216例随访(中位5.2年)中,3例(1.5%)远处转移,均在初诊时发现,肿瘤均呈100%滤泡生长伴包膜或血管侵犯;全队列无局部区域复发。
关键数值与推荐
- NIFTP诊断标准应恢复为无真性乳头(而非<1%乳头)。
临床怎么用
- 对于单发包裹性甲状腺乳头状癌,若乳头比例<1%,可考虑诊断为NIFTP,避免癌的诊断和不必要的治疗。
- 乳头比例≥1%提示淋巴结转移风险,需评估淋巴结状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The percentage of papillae is a crucial criterion in differentiating noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) from papillary thyroid carcinomas (PTCs) and in subclassifying PTC into classic and follicular variant. Since the description of NIFTP, three studies have shown that the presence of any papillae may be associated with nodal metastasis, which led to modification of the NIFTP criterion from <1% papillae to no true papillae allowed. We aim at providing clinical evidence-based data on the impact that papillary growth has on nodal spread and tumor genotype in tumors previously diagnosed as encapsulated unifocal PTC. Methods: A meticulous histopathologic examination was performed on 235 cases previously diagnosed as unifocal encapsulated PTC (U-EPTC). One hundred of these cases were subjected to BRAFV600E and NRASQ61R immunohistochemistry. Results: In our cohort, 27 patients (12%) had lymph node metastasis (N1) at the time of initial resection. Overall, 89% of the tumors in the N1 group contained ≥50% papillae, compared with 13% in the N0/Nx group. Nodal metastases were only present in tumors with ≥1% papillae. In noninvasive U-EPTC (n = 161), N1 disease was seen only in tumors with ≥10% papillae. A higher percentage of papillae within the tumor also correlated with an increased frequency of BRAFV600E and decreased rate of NRASQ61R. None of the 26 NRAS-positive cases had nodal disease, including the invasive tumors. Among 216 patients with follow-up (median: 5.2 years), 3 patients (1.5%) had distant metastases, all detected at the initial presentation. All three tumors displayed 100% follicular growth, and capsular or vascular invasion. There was no locoregional recurrence in the entire cohort. Conclusion: In U-EPTC, there is a strong correlation between high percentage of papillary growth, presence of nodal metastasis, and BRAF+/RAS- genotype regardless of invasive status. Nodal metastases were not seen in tumors with <1% papillae irrespective of invasive status. These findings indicate that the initial criterion of <1% papillae is still valid for the diagnosis of NIFTP. Reinstituting this criterion will spare a carcinoma diagnosis and unnecessary therapy with its side effects on patients who have negligible clinical risk.
引用
- Xu B, Serrette R, Tuttle RM, et al. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2019. PMID: 31452453. doi:10.1089/thy.2019.0328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。